Gestational diabetes (GDM) has an estimated incidence of 3–10%, depending upon geography and ethnic origin; it is considered by many to be a major health concern for the mother and fetus. Dietary modification and pharmacological therapy are the principal means employed to control maternal hyperglycemia. The two main pharmacological options for GDM management are administration of insulin or the use of oral hypoglycaemic and anti-hyperglycaemic drugs. Although controversy continues regarding the need for hypoglycaemic agents in all GDM women, approximately 30–60% do require pharmacological therapy in order to maintain targeted levels of glycaemic control.